Our news

• St. Petersburg International Economic Forum-2013. Knowledge-based economy – a strategy for getting ahead of the curve

  24 June 2013

  

  During SPIEF 2013 panel “Knowledge-based economy – a strategy for getting ahead of the curve”, one of the moderators of which was Leonid Melamed (Member of the Board of Directors, RusnanoMedInvest and NovaMedica; Chairman of the Board of Directors, Team Drive), the panelists featuring science, education, government and investment banking have shared their views on the viability and prospects for further development of the knowledge-based economy in Russia as the highest stage in the development of innovative economy putting together specific proposals/ideas in favor of their viewpoints. 

• St. Petersburg International Economic Forum. How to increase the role of the Russian pharmaceutical industry in the world market?

  24 June 2013

  

  Leonid Melamed, Chairman of the Board of Directors, Team Drive; Member of the Board of Directors, RosnanoMedInvest an NovaMedica: "The State policy shall be focused on having as much elements in the pharmaceutical value creation chain concentrated in the hands of as many Russia-based companies paying taxes in Russia as possible."

• S.Fyodorov Eye Microsurgery Complex and NovaMedica have signed a cooperation agreement on localizing innovative ophthalmic treatment technologies in Russia

  03 June 2013

  

  S.Fyodorov Eye Microsurgery Complex Federal State Institution and NovaMedica (a pharmaceutical subsidiary of RUSNANO and Domain Associates) have signed an agreement that covers cooperation on localization of innovative ophthalmic products and technologies sourced from around the globe to be developed and produced in Russia. 

• Fabrice Egros, Deputy CEO of NovaMedica, on BIO-2013: "NovaMedica is an integral part of the Russian Government’s Healthcare strategy "

  25 April 2013

  

  New pharmaceutical company NovaMedica is an integral part of this Russian Government’s Healthcare strategy within “Russia 2020” that will boost growth in the Pharmaceutical Market for the next 10 years.

• Announce: Novamedica on BIO 2013: Spotlight On The BRICs. Russia

  19 April 2013

  

  BIO International Convention (BIO-2013). Chicago, USA. Special session «Spotlight on the BRICs: Russia» Monday, Apr 22, 2013 

• NovaMedica launches its website using a new domain name www.novamedica.com

  18 April 2013

  Pharmaceutical company NovaMedica announces the launch of its website using a new domain name www.novamedica.com. One of the main reasons for moving the website to a new domain that would be more consistent with the сompany’s name is our desire to offer our current and potential partners an easier access to the information about the сompany.

• Regulatory changes in the procedure of expert review and registration of new drugs are needed towards localization of innovative pharmaceutical products in Russia – Vladimir Gurdus

  02 April 2013

  

  "To improve quality and safety of new drugs to be introduced to the Russian market and for localization of innovative pharmaceutical products in the country, the expert review and registration of such products require procedural changes”, - Vladimir Gurdus, CEO of D-Pharma, LLC, a managing company of “RusnanoMedInvest” and “NovaMedica” projects stated at the Conference “State regulation and the Russian pharmaceutical industry 2013: continuation of the dialogue”.

• Developed market of technology transfer shall be in place to ensure the needs for novel products are met in the Russian pharmaceutical industry – Mikhail Getman

  26 March 2013

  

  "Developed market of technology transfer shall be in place to ensure the needs for novel products are met in the Russian pharmaceutical industry”, - said Mikhail Getman, VP for R&D and Regulatory Affairs of NovaMedica, LLC at the 1^st meeting of the Subcommittee for international cooperation in modernization and innovations in healthcare and pharmaceutical industry of the Russian Chamber of Commerce and Trade.

• RusnanoMedInvest and Domain Associates to invest $93m in development of three next-generation pharmaceuticals

  19 December 2012

  U.S. venture capital firm Domain Associates, Rusnano subsidiary RusnanoMedInvest (RMI) and a group of co-investors will invest a combined $93m in Marinus Pharmaceuticals, Inc., Lithera, Inc., and Regado Biosciences, Inc., all of which are developers of advanced pharmaceutical products.

• The production site of the Russian pharmaceutical company NovaMedica will be chosen in the 1st quarter of 2013

  13 November 2012

  The identification of location of the production site of a new pharmaceutical company NovaMedica, a joint enterprise betweenthe Russian high-technology investment fund RUSNANO and the American venture healthcare fund Domain Associates will be chosen at the end of the first quarter of 2013.